Q-omics provides the consensus-scored PLD5 profile across patient tissues and cancer cell-line models. PLD5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PLD5 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, PLD5 RNA expression shows 15,783 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, THCA, and THYM as cancer lineages where PLD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLD5 survival associations across molecular data types. PLD5 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLD5 RNA expression–survival associations across cancer types. High PLD5 expression shows unfavorable associations in KIRP, ACC, LGG, KICH and THCA, but favorable associations in HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PLD5 RNA expression.
This table summarizes PLD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PLD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLD5 shows lower tumor expression in THCA, COAD, KICH, KIRC and BRCA and higher tumor expression in LUAD. The THCA box plot shows higher PLD5 RNA expression in normal versus tumor tissue (log2 FC = −0.390, t-test p < 0.001).
This table shows molecular features associated with PLD5 in patient tissues and cancer cell lines. In patient samples, PLD5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_SCLC.
